Switch theme
Sign up to access all valuation multiples
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
2015
22
LTM Revenue $24K
Last FY EBITDA -$42.6M
$152M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
INmune Bio has a last 12-month revenue (LTM) of $24K and a last 12-month EBITDA of n/a.
In the most recent fiscal year, INmune Bio achieved revenue of $14K and an EBITDA of -$42.6M.
INmune Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See INmune Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $24K | XXX | $14K | XXX | XXX | XXX |
| Gross Profit | $24K | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$42.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -304536% | XXX | XXX | XXX |
| EBIT | -$43.2M | XXX | -$42.6M | XXX | XXX | XXX |
| EBIT Margin | -182067% | XXX | -304536% | XXX | XXX | XXX |
| Net Profit | -$42.6M | XXX | -$42.1M | XXX | XXX | XXX |
| Net Margin | -179519% | XXX | -300586% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, INmune Bio's stock price is $7.
INmune Bio has current market cap of $171M, and EV of $152M.
See INmune Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $152M | $171M | XXX | XXX | XXX | XXX | $-1.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, INmune Bio has market cap of $171M and EV of $152M.
INmune Bio's trades at 10878.8x EV/Revenue multiple, and -3.6x EV/EBITDA.
Equity research analysts estimate INmune Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
INmune Bio has a P/E ratio of -4.0x.
See valuation multiples for INmune Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $171M | XXX | $171M | XXX | XXX | XXX |
| EV (current) | $152M | XXX | $152M | XXX | XXX | XXX |
| EV/Revenue | 6420.3x | XXX | 10878.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.6x | XXX | XXX | XXX |
| EV/EBIT | -3.5x | XXX | -3.6x | XXX | XXX | XXX |
| EV/Gross Profit | 6420.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.0x | XXX | -4.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialINmune Bio's last 12 month revenue growth is 9426%
INmune Bio's revenue per employee in the last FY averaged $1K, while opex per employee averaged $1.9M for the same period.
INmune Bio's rule of 40 is -9762% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
INmune Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for INmune Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9426% | XXX | 1866% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -304536% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -9762% | XXX | -295110% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 236900% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 304636% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
INmune Bio acquired XXX companies to date.
Last acquisition by INmune Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . INmune Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was INmune Bio founded? | INmune Bio was founded in 2015. |
| Where is INmune Bio headquartered? | INmune Bio is headquartered in United States of America. |
| How many employees does INmune Bio have? | As of today, INmune Bio has 22 employees. |
| Who is the CEO of INmune Bio? | INmune Bio's CEO is Dr. Raymond J. Tesi, M.D.. |
| Is INmune Bio publicy listed? | Yes, INmune Bio is a public company listed on NAS. |
| What is the stock symbol of INmune Bio? | INmune Bio trades under INMB ticker. |
| When did INmune Bio go public? | INmune Bio went public in 2019. |
| Who are competitors of INmune Bio? | Similar companies to INmune Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of INmune Bio? | INmune Bio's current market cap is $171M |
| What is the current revenue of INmune Bio? | INmune Bio's last 12 months revenue is $24K. |
| What is the current revenue growth of INmune Bio? | INmune Bio revenue growth (NTM/LTM) is 9426%. |
| What is the current EV/Revenue multiple of INmune Bio? | Current revenue multiple of INmune Bio is 6420.3x. |
| Is INmune Bio profitable? | Yes, INmune Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
